{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:48:46Z","timestamp":1792180126928,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T00:00:00Z","timestamp":1354147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T00:00:00Z","timestamp":1354147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>The aim of this study was to examine whether circulating levels of the pro-inflammatory glycoprotein tenascin-C (TNC) are elevated in musculoskeletal disorders including rheumatoid arthritis (RA) and to assess in RA whether levels are related to clinical disease status and\/or patient response to treatment.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>TNC in serum or plasma was quantified by ELISA. Samples from 4 cohorts of RA patients were examined and compared to normal human subjects and to patients with other inflammatory diseases.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Circulating TNC levels were significantly raised in patients with RA, as well as patients with systemic lupus erythematosus, idiopathic inflammatory myositis, psoriatic arthritis and ankylosing spondylitis, whilst patients with Sjogren's syndrome displayed levels similar to healthy controls. The highest levels of TNC were observed in RA patients with late stage disease. In early disease TNC levels correlated positively with ultrasound determined erosion scores. Treatment of early RA patients with infliximab plus methotrexate (MTX) resulted in a transient decrease in circulating TNC over the first year of therapy. In contrast, TNC levels increased over time in RA patients receiving MTX alone. In patients treated with infliximab plus MTX, baseline TNC levels significantly correlated with tender joint counts (TJC) at 18 and 54 weeks after initiation of infliximab therapy.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Raised circulating TNC levels are detected in specific inflammatory diseases. Levels are especially high in RA where they may act as a biomarker of bone erosion and a predictor of the effect of infliximab on RA patient joint pain.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4105","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T17:11:02Z","timestamp":1354209062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Raised circulating tenascin-C in rheumatoid arthritis"],"prefix":"10.1186","volume":"14","author":[{"given":"Theresa H","family":"Page","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M","family":"Piccinini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Nicolaidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim S","family":"Midwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,29]]},"reference":[{"key":"3842_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010, 69: 631-637. 10.1136\/ard.2009.123919.","journal-title":"Ann Rheum Dis"},{"key":"3842_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/ard.2010.135376","volume":"70","author":"JD Isaacs","year":"2011","unstructured":"Isaacs JD, Ferraccioli G: The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis. 2011, 70: 4-7. 10.1136\/ard.2010.135376.","journal-title":"Ann Rheum Dis"},{"key":"3842_CR3","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1136\/ard.2011.154252","volume":"70","author":"P Miossec","year":"2011","unstructured":"Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdottir S, Rao R, Tsouderos Y, Reginster JY: Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis. 2011, 70: 1713-1718. 10.1136\/ard.2011.154252.","journal-title":"Ann Rheum Dis"},{"key":"3842_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1615\/CritRevImmunol.v31.i2.30","volume":"31","author":"IA Udalova","year":"2011","unstructured":"Udalova IA, Ruhmann M, Thomson SJ, Midwood KS: Expression and immune function of tenascin-C. Crit Rev Immunol. 2011, 31: 115-145. 10.1615\/CritRevImmunol.v31.i2.30.","journal-title":"Crit Rev Immunol"},{"key":"3842_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s12079-009-0075-1","volume":"3","author":"KS Midwood","year":"2009","unstructured":"Midwood KS, Orend G: The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009, 3: 287-310. 10.1007\/s12079-009-0075-1.","journal-title":"J Cell Commun Signal"},{"key":"3842_CR6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nm.1987","volume":"15","author":"K Midwood","year":"2009","unstructured":"Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F, Foxwell B: Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009, 15: 774-780. 10.1038\/nm.1987.","journal-title":"Nat Med"},{"key":"3842_CR7","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.4049\/jimmunol.0900725","volume":"182","author":"M Kanayama","year":"2009","unstructured":"Kanayama M, Kurotaki D, Morimoto J, Asano T, Matsui Y, Nakayama Y, Saito Y, Ito K, Kimura C, Iwasaki N, Suzuki K, Harada T, Li HM, Uehara J, Miyazaki T, Minami A, Kon S, Uede T: Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol. 2009, 182: 8015-8025. 10.4049\/jimmunol.0900725.","journal-title":"J Immunol"},{"key":"3842_CR8","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.4049\/jimmunol.1101524","volume":"187","author":"M Kanayama","year":"2011","unstructured":"Kanayama M, Morimoto J, Matsui Y, Ikesue M, Danzaki K, Kurotaki D, Ito K, Yoshida T, Uede T: alpha9beta1 integrin-mediated signaling serves as an intrinsic regulator of pathogenic Th17 cell generation. J Immunol. 2011, 187: 5851-5864. 10.4049\/jimmunol.1101524.","journal-title":"J Immunol"},{"key":"3842_CR9","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/art.34401","volume":"64","author":"M Ruhmann","year":"2012","unstructured":"Ruhmann M, Piccinini AM, Kong PL, Midwood KS: Endogenous activation of adaptive immunity: Tenascin-C drives IL-17 synthesis in arthritic joint disease. Arthritis Rheum. 2012, 64: 2179-2190. 10.1002\/art.34401.","journal-title":"Arthritis Rheum"},{"key":"3842_CR10","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.4049\/jimmunol.0903359","volume":"184","author":"FG Goh","year":"2010","unstructured":"Goh FG, Piccinini AM, Krausgruber T, Udalova IA, Midwood KS: Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol. 2010, 184: 2655-2662. 10.4049\/jimmunol.0903359.","journal-title":"J Immunol"},{"key":"3842_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/art.1780351011","volume":"35","author":"SS McCachren","year":"1992","unstructured":"McCachren SS, Lightner VA: Expression of human tenascin in synovitis and its regulation by interleukin-1. Arthritis Rheum. 1992, 35: 1185-1196. 10.1002\/art.1780351011.","journal-title":"Arthritis Rheum"},{"key":"3842_CR12","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/art.1780370706","volume":"37","author":"X Chevalier","year":"1994","unstructured":"Chevalier X, Groult N, Larget-Piet B, Zardi L, Hornebeck W: Tenascin distribution in articular cartilage from normal subjects and from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1994, 37: 1013-1022. 10.1002\/art.1780370706.","journal-title":"Arthritis Rheum"},{"key":"3842_CR13","first-page":"1439","volume":"19","author":"M Cutolo","year":"1992","unstructured":"Cutolo M, Picasso M, Ponassi M, Sun MZ, Balza E: Tenascin and fibronectin distribution in human normal and pathological synovium. J Rheumatol. 1992, 19: 1439-1447.","journal-title":"J Rheumatol"},{"key":"3842_CR14","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/rheumatology\/32.9.780","volume":"32","author":"DM Salter","year":"1993","unstructured":"Salter DM: Tenascin is increased in cartilage and synovium from arthritic knees. Br J Rheumatol. 1993, 32: 780-786. 10.1093\/rheumatology\/32.9.780.","journal-title":"Br J Rheumatol"},{"key":"3842_CR15","first-page":"2021","volume":"31","author":"M Hasegawa","year":"2004","unstructured":"Hasegawa M, Hirata H, Sudo A, Kato K, Kawase D, Kinoshita N, Yoshida T, Uchida A: Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol. 2004, 31: 2021-2026.","journal-title":"J Rheumatol"},{"key":"3842_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/jor.20366","volume":"25","author":"M Hasegawa","year":"2007","unstructured":"Hasegawa M, Nakoshi Y, Muraki M, Sudo A, Kinoshita N, Yoshida T, Uchida A: Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. J Orthop Res. 2007, 25: 563-568. 10.1002\/jor.20366.","journal-title":"J Orthop Res"},{"key":"3842_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/art.21544","volume":"54","author":"PC Taylor","year":"2006","unstructured":"Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, Marsters PA, Wagner CL, Maini RN: Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum. 2006, 54: 47-53. 10.1002\/art.21544.","journal-title":"Arthritis Rheum"},{"key":"3842_CR18","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.jacc.2006.03.033","volume":"47","author":"A Sato","year":"2006","unstructured":"Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M: Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol. 2006, 47: 2319-2325. 10.1016\/j.jacc.2006.03.033.","journal-title":"J Am Coll Cardiol"},{"key":"3842_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1253\/circj.71.327","volume":"71","author":"F Terasaki","year":"2007","unstructured":"Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A: Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J. 2007, 71: 327-330. 10.1253\/circj.71.327.","journal-title":"Circ J"},{"key":"3842_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1478-3231.2005.01229.x","volume":"26","author":"H Tanaka","year":"2006","unstructured":"Tanaka H, El-Karef A, Kaito M, Kinoshita N, Fujita N, Horiike S, Watanabe S, Yoshida T, Adachi Y: Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver Int. 2006, 26: 311-318. 10.1111\/j.1478-3231.2005.01229.x.","journal-title":"Liver Int"},{"key":"3842_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s003840100312","volume":"16","author":"S Riedl","year":"2001","unstructured":"Riedl S, Tandara A, Reinshagen M, Hinz U, Faissner A, Bodenmuller H, Buhr HJ, Herfarth C, Moller P: Serum tenascin-C is an indicator of inflammatory bowel disease activity. Int J Colorectal Dis. 2001, 16: 285-291. 10.1007\/s003840100312.","journal-title":"Int J Colorectal Dis"},{"key":"3842_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ijc.2910600121","volume":"60","author":"S Schenk","year":"1995","unstructured":"Schenk S, Muser J, Vollmer G, Chiquet-Ehrismann R: Tenascin-C in serum: an acute-phase protein or a carcinoma marker?. Int J Cancer. 1995, 60: 145-10.1002\/ijc.2910600121.","journal-title":"Int J Cancer"},{"key":"3842_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2741\/E170","volume":"2","author":"R Perrotta","year":"2010","unstructured":"Perrotta R, Bevelacqua Y, Malaguarnera G, Paladina I, Giordano M, Malaguarnera M: Serum markers of cutaneous melanoma. Front Biosci (Elite Ed). 2010, 2: 1115-1122.","journal-title":"Front Biosci (Elite Ed)"},{"key":"3842_CR24","doi-asserted-by":"publisher","first-page":"e4599","DOI":"10.1371\/journal.pone.0004599","volume":"4","author":"SD Amonkar","year":"2009","unstructured":"Amonkar SD, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, Seshaiah P, Yip P, Mansfield BC: Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One. 2009, 4: e4599-10.1371\/journal.pone.0004599.","journal-title":"PLoS One"},{"key":"3842_CR25","first-page":"489","volume":"25","author":"T Ishiwata","year":"2005","unstructured":"Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, Shimizu K, Miura K, Fukuchi Y: Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res. 2005, 25: 489-495.","journal-title":"Anticancer Res"},{"key":"3842_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ijc.2910610402","volume":"61","author":"S Schenk","year":"1995","unstructured":"Schenk S, Muser J, Vollmer G, Chiquet-Ehrismann R: Tenascin-C in serum: a questionable tumor marker. Int J Cancer. 1995, 61: 443-449. 10.1002\/ijc.2910610402.","journal-title":"Int J Cancer"},{"key":"3842_CR27","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1007\/s00018-011-0783-6","volume":"68","author":"KS Midwood","year":"2011","unstructured":"Midwood KS, Hussenet T, Langlois B, Orend G: Advances in tenascin-C biology. Cell Mol Life Sci. 2011, 68: 3175-3199. 10.1007\/s00018-011-0783-6.","journal-title":"Cell Mol Life Sci"},{"key":"3842_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/nm.2379","volume":"17","author":"T Oskarsson","year":"2011","unstructured":"Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massague J: Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011, 17: 867-874. 10.1038\/nm.2379.","journal-title":"Nat Med"},{"key":"3842_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1091\/mbc.5.4.439","volume":"5","author":"P Tremble","year":"1994","unstructured":"Tremble P, Chiquet-Ehrismann R, Werb Z: The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell. 1994, 5: 439-453.","journal-title":"Mol Biol Cell"},{"key":"3842_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrrheum.2009.179","volume":"5","author":"WB van den Berg","year":"2009","unstructured":"van den Berg WB, Miossec P: IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol. 2009, 5: 549-553. 10.1038\/nrrheum.2009.179.","journal-title":"Nat Rev Rheumatol"},{"key":"3842_CR31","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.4049\/jimmunol.167.2.1004","volume":"167","author":"E Lubberts","year":"2001","unstructured":"Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, van de Loo FA, van den Berg WB: IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol. 2001, 167: 1004-1013.","journal-title":"J Immunol"},{"key":"3842_CR32","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/art.24329","volume":"60","author":"JP van Hamburg","year":"2009","unstructured":"van Hamburg JP, Mus AM, de Bruijn MJ, de Vogel L, Boon L, Cornelissen F, Asmawidjaja P, Hendriks RW, Lubberts E: GATA-3 protects against severe joint inflammation and bone erosion and reduces differentiation of Th17 cells during experimental arthritis. Arthritis Rheum. 2009, 60: 750-759. 10.1002\/art.24329.","journal-title":"Arthritis Rheum"},{"key":"3842_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s004030000152","volume":"292","author":"MA Latijnhouwers","year":"2000","unstructured":"Latijnhouwers MA, de Jongh GJ, Bergers M, de Rooij MJ, Schalkwijk J: Expression of tenascin-C splice variants by human skin cells. Arch Dermatol Res. 2000, 292: 446-454. 10.1007\/s004030000152.","journal-title":"Arch Dermatol Res"},{"key":"3842_CR34","first-page":"147","volume":"35","author":"Y Nakoshi","year":"2008","unstructured":"Nakoshi Y, Hasegawa M, Sudo A, Yoshida T, Uchida A: Regulation of tenascin-C expression by tumor necrosis factor-alpha in cultured human osteoarthritis chondrocytes. J Rheumatol. 2008, 35: 147-152.","journal-title":"J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4105\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:48:34Z","timestamp":1728384514000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,12]]}},"alternative-id":["3842"],"URL":"https:\/\/doi.org\/10.1186\/ar4105","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]},"assertion":[{"value":"11 July 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R260"}}